NEW YORK (GenomeWeb) – Biodesy said today it has closed a $10 million Series B financing round led by existing investors 5AM Ventures, Pfizer Venture Investments, and Roche Venture Fund.
The company said that proceeds from the round would be used to expand and accelerate commercialization of its Delta System, a high-throughput platform for measuring protein conformational change.
The company also today announced that the platform is now available worldwide.
Biodesy has targeted the Delta System toward drug researchers as a tool for drug screening, hit evaluation, and mechanism of action studies. According to the company, its 20 customers include seven of the top 10 global pharmaceutical firms, and it has developed assays for roughly 100 protein constructs representing approximately 40 different proteins and more than 10 different drug target classes.